Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
89 hedge funds and large institutions have $317M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 34 increasing their positions, 19 reducing their positions, and 10 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
90% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 10
79% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 19
32% more capital invested
Capital invested by funds: $240M → $317M (+$76.4M)
11% more funds holding
Funds holding: 80 → 89 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$14.5M |
| 2 |
BlackRock
New York
|
+$8.58M |
| 3 |
DM
Deerfield Management
New York
|
+$5.58M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$18.4M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$6.22M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.26M |
| 4 |
AIC
AWM Investment Company
New York
|
-$3.12M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$2.59M |
RETA Hedge Fund Activity: Q4 2017 in Review
89 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q4 2017, worth a combined $317M — up 32% from $240M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new RETA positions and 10 closed out — a net gain of 9 holders — while 34 added to existing stakes and 19 trimmed.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $14.5M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $18.4M sold.
- 89 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q4 2017, up from 80 in Q3 2017.
- Funds reported $317M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q4 2017, up 32% quarter-over-quarter.
- 19 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q4 2017 and 10 closed out, a net change of +9 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q4 2017 was Laurion Capital Management, an estimated $14.5M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q4 2017 was Novo Holdings A/S, an estimated $18.4M sold.
Based on aggregated 13F filings for Q4 2017.